Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zebinuron is a neurotropic supplement combination developed by Resilient Cosmeceuticals, primarily indicated for the management of diabetic neuropathy, alcoholic neuropathy, and drug-induced neuropathy. The formulation typically consists of a fixed-dose combination of methylcobalamin, alpha-lipoic acid, pyridoxine hydrochloride (Vitamin B6), and folic acid (Vitamin B9). Methylcobalamin, a bioactive form of Vitamin B12, is essential for the synthesis of the myelin sheath and promotes nerve regeneration. Alpha-lipoic acid serves as a potent antioxidant that reduces oxidative stress and improves nerve conduction velocity and blood flow to peripheral nerves. Pyridoxine and folic acid act as vital cofactors in neurotransmitter synthesis and cellular metabolic processes, collectively supporting the repair and maintenance of the nervous system.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zebinuron.